US Prostate Cancer Diagnostics and Therapeutics Market 2026-2035

US Prostate Cancer Diagnosis & Treatment Market Size, Share & Trends Analysis Report by Diagnostic Technique (Prostate Specific Antigen Test, Digital Rectal Exam), by Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy) Forecast Period, 2026–2035

Industry Overview

US prostate cancer diagnosis & treatment market was valued at $8,250.5 million in 2025 and is projected to reach $20,091.0 million by 2035, growing at a CAGR of 9.4% during the forecast period (2026-2035). The market is growing due to the increasing incidence of prostate cancer, particularly among the aging male population. Rising awareness regarding early screening through prostate-specific antigen testing and digital rectal examination is contributing to higher diagnosis rates. Continuous advancements in diagnostic technologies and imaging accuracy are improving early detection and risk stratification. Expanding availability of advanced therapeutic options, including immunotherapy and targeted therapy, is enhancing treatment outcomes and patient survival. In addition, supportive reimbursement frameworks and strengthening oncology infrastructure across emerging and developed economies are reinforcing sustained market expansion.

Market Dynamics

Rising Disease Burden and Expanding Diagnostic Adoption

The rising incidence of prostate cancer, particularly among men above 60 years of age, remains a primary growth driver for the prostate cancer diagnosis and treatment market. Demographic shifts toward an aging population are directly increasing the patient pool requiring routine screening, confirmatory diagnostics, and long-term therapeutic management. Clinical guidelines in several countries recommend regular prostate-specific antigen testing and digital rectal examination for high-risk groups, supporting consistent diagnostic volumes. Improvements in laboratory accuracy, biomarker validation, and imaging integration are strengthening early-stage detection rates. Earlier diagnosis is leading to higher treatment initiation, thereby sustaining demand across hormonal therapy, radiation therapy, chemotherapy, immunotherapy, and targeted therapy segments.

Advancements in Therapeutic Innovation and Clinical Infrastructure

Continuous advancement in treatment innovation and precision oncology represents another major driver for market expansion. Pharmaceutical companies are expanding pipelines focused on next-generation hormonal agents, radioligand therapies, and immune-based approaches designed to improve survival outcomes in advanced and metastatic cases. Regulatory approvals for novel targeted therapies are broadening the available treatment landscape and encouraging earlier adoption in clinical practice. Expansion of specialized oncology centers and improved access to reimbursement in key healthcare systems are increasing therapy uptake. Growing clinical research activity and participation in oncology trials are accelerating the introduction of differentiated therapeutic options, reinforcing sustained market growth.

Market Segmentation

• Based on diagnostic technique, the market is segmented into prostate-specific antigen test and digital rectal exam.
• Based on therapy, the market is segmented into hormonal therapy, chemotherapy, immunotherapy, radiation therapy, and targeted therapy.

Molecular Imaging Reshaping Prostate Cancer Detection

PSMA-based PET imaging has emerged as the dominant diagnostic sub-segment within the US prostate cancer diagnostics landscape, supported by its superior sensitivity in identifying both localized and metastatic disease. Expanding screening initiatives and improved imaging infrastructure across oncology centers are strengthening clinical reliance on this technology. Growing disease incidence, with more than 288,000 new prostate cancer cases reported annually in the United States, continues to push demand for accurate early-stage detection tools. Technology providers such as Siemens Healthineers, GE HealthCare, and Lantheus have expanded imaging systems and radiotracer portfolios to support this diagnostic shift. Increasing use of fluorine-18–based tracers and PSMA-targeted agents is improving diagnostic precision and clinical decision-making. Recent regulatory approvals for next-generation PET imaging agents have further accelerated adoption, reinforcing molecular imaging as a central component of modern prostate cancer care pathways.

Targeted Radioligand Therapy Accelerating Precision Treatment

Radioligand therapy targeting prostate-specific membrane antigen has developed into one of the fastest expanding therapeutic sub-segments in the US prostate cancer treatment market. The approach combines targeted molecules with radioactive isotopes, enabling radiation delivery directly to cancer cells while limiting damage to surrounding tissue. Growing adoption of precision oncology and strong reimbursement structures are supporting rapid clinical integration of these therapies. Major pharmaceutical companies including Novartis, Bayer, and AstraZeneca are investing heavily in radiopharmaceutical research and manufacturing capacity to meet increasing demand. Ongoing innovation in isotope production and PSMA-targeted drug development continues to expand the eligible patient population. Large-scale investments in radioligand manufacturing facilities in the United States also highlight the accelerating commercialization of these treatments across the oncology ecosystem.

Market Players Outlook

The major companies operating in the US prostate cancer diagnostic and therapeutic market include Astellas Pharma Inc., Pfizer Inc., Johnson & Johnson (Janssen), Novartis AG, AstraZeneca plc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In February 2026, Astellas and Vir Biotechnology have entered a global collaboration to develop VIR-5500, an experimental PSMA-targeting T-cell engager for advanced prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC).
• In November 2023, Pfizer’s co-developed XTANDI (enzalutamide) with Astellas has continued clinical momentum with expanded indications based on the Phase 3 EMBARK trial (nmCSPC with biochemical recurrence), offering new treatment options in earlier stages of prostate cancer.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the US prostate cancer diagnostic and therapeutic market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.

Show more